Observational study of lymphoma patients in Italy
Studio Osservazionale Retrospettivo Di Coorte Italiana Di Pazienti Con Linfoma (RETRO-LYMPH)
IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06781437
This study looks at lymphoma patients in Italy to see how different factors affect their treatment and survival over the years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna (other) |
| Locations | 1 site (Bologna, Bologna) |
| Trial ID | NCT06781437 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes data from lymphoma patients diagnosed between January 1980 and September 2021 at a single center in Italy. It aims to identify clinical and epidemiological factors that influence disease progression and treatment outcomes. The study will also document various therapies, treatment durations, interruptions, and associated adverse events. By examining patient survival rates, the research seeks to enrich the understanding of lymphoma and lymphoproliferative syndromes for future studies.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 18 and older who were diagnosed with lymphoma or lymphoproliferative syndrome between January 1980 and September 2021.
Not a fit: Patients who were diagnosed with lymphoma or lymphoproliferative syndrome outside the specified time frame will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the factors affecting lymphoma progression and treatment efficacy, potentially improving patient care.
How similar studies have performed: While observational studies on lymphoma exist, this specific retrospective approach focusing on a long time frame and detailed patient data is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age greater than or equal to 18 years of enrollment * Diagnosis of lymphoma or lymphoproliferative syndrome between January 1980 and September 2021 * Signature of the informed consent form where applicable Exclusion Criteria: * none
Where this trial is running
Bologna, Bologna
- IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Bologna, Italy (RECRUITING)
Study contacts
- Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Pier Luigi Zinzani, MD
- Email: pierluigi.zinzani@unibo.it
- Phone: +390512143680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoproliferative Syndrome, Autoimmune, Lymphoma